
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
ERT has announced
Joe Eazor is the CEO of the merged company, and the management team will be composed of a combination of both ERT and Bioclinica executives.
For more information, click






